Oral etoposide in the treatment of hormone‐refractory prostate cancer

Maha H. Hussain*, Kenneth J. Pienta, Bruce G. Redman, Glenn D. Cummings, Lawrence E. Flaherty

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

48 Scopus citations


Background. Hormone‐refractory prostate cancer generally remains a chemotherapy‐resistant tumor and therefore warrants the continued evaluation of promising agents. Methods. Twenty‐two eligible patients with hormone‐refractory prostate cancer were treated with oral etoposide at a dosage of 50 mg/m2/day for 21 days in a 28‐day cycle. Response was evaluated using standard solid tumor response criteria. Results. There were two partial responses of 6 and 14 months' duration, respectively. Two patients had disease stabilization, one for 6 months and one for 12 months. Median survival was 31 weeks, with an overal 1‐year survival of 30%. Reversible alopecia and myelosuppression were the primary toxicities noted. Conclusions. Single‐agent oral etoposide has minimal activity in patients with hormone‐refractory prostate cancer.

Original languageEnglish (US)
Pages (from-to)100-103
Number of pages4
Issue number1
StatePublished - Jan 1 1994


  • chemotherapy
  • hormone refractory prostate cancer
  • oral etoposide

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Oral etoposide in the treatment of hormone‐refractory prostate cancer'. Together they form a unique fingerprint.

Cite this